Arcadia Biosciences discloses CEO/CFO compensation: $260k/$212k salary, stock options at $2.71

Arcadia Biosciences, Inc.

CEO Thomas Schaefer base salary $260k/yr; 2024 target bonus 50% as CEO, 40% as CFO prorated.
CFO Mark Kawakami base salary $212,063/yr; 2024 target bonus 30% as CFO, 20% as VP Finance prorated.
Each granted options to buy 20,000 shares at $2.71, vesting over 4 years (25% one-year cliff, 36 monthly).
Schaefer and Kawakami receive 6-month severance (non-CIC) or 12-month plus full equity vest (CIC).
Agreements expire third anniversary of July 5, 2024; at-will employment confirmed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.